



2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Virtual): Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at 2021 ASCO Annual Meeting below and refer to the Congress Links section available on our Medical Information website which may include additional information.

RENAL CELL CARCINOMA

1. Grünwald V, Powles T, Kopyltsov E, et al. Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Hutson T, Choueiri TK, Motzer R, et al. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) vs sunitinib (SUN) treatment arms. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
3. Lee CH, Li C, Perini RF, et al. KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
4. Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) vs sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Oral presentation at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
5. Plimack ER, Hammers HJ, Choueiri TK, et al. A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
6. Lee CH, Shah AY, Hsieh JJ, et al. Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial. *J Clin Oncol*. 2021.

HEPATOCELLULAR CARCINOMA

1. Macarulla T, Moreno V, Chen LT, et al. Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC). Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Trueman D, Liu Y, Geadah M, et al. The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
3. Zhu AX, Llovet JM, Kobayashi M, et al. Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC). Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
4. Kudo M, Izumi N, Motomura K, et al. A multicenter observational study of lenvatinib for unresectable hepatocellular carcinoma in Japan. *J Clin Oncol*. 2021.
5. Liu Y, Trueman D, Lucero M, et al. The comparative efficacy atezolizumab and bevacizumab vs. lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). *J Clin Oncol*. 2021.
6. Okusaka T, Kudo M, Ikeda K, et al. Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC). *J Clin Oncol*. 2021.
7. Singal AG, Nagar S, Hitchens A, et al. Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices. *J Clin Oncol*. 2021.

ENDOMETRIAL CANCER

1. Corman S, Kelkar S, Odak S, et al. Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer in the United States: Endometrial Cancer Health Outcomes (ECHO) retrospective chart review study. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Lorusso D, Colombo N, Herraes AC, et al. Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC). Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
3. Zhao Q, Hughes R, Altaf-Haroon I, et al. Systematic literature review of the real-world burden and use of chemotherapies for treatment of advanced or recurrent endometrial carcinoma. *J Clin Oncol*. 2021.

BREAST CANCER

1. Hamilton EP, Wang JS, Pluard TJ, et al. Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Poster discussion at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Johnston SRD, Pluard TJ, Wang JS, et al. Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. *J Clin Oncol*. 2021.
3. Mougalian SS, Zhang J, Kish J, et al. Real-world clinical effectiveness of eribulin in metastatic breast cancer patients with visceral metastases in the United States. *J Clin Oncol*. 2021.
4. Xiao JA, Coleman HA, Sahmoud T, et al. Relative Bioavailability of H3B-6545 Tablets vs Capsules and Drug-Drug Interaction between H3B-6545 and Pantoprazole. *J Clin Oncol*. 2021.

GASTRIC CANCER

1. Chung HC, Lwin Z, Gomez-Roca C, et al. LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Yamaguchi K, Iwasa S, Hirao M, et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.

COLORECTAL CANCER

1. Gomez-Roca C, Yanez E, Im SA, et al. LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.

MELANOMA

1. Arance A, de la Cruz-Merino, Petrella TM, et al. Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004. Oral presentation at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.

BILIARY TRACT CANCER

1. Villanueva L, Lwin Z, Chung HC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.

ADDITIONAL STUDIES

1. Morgan G, Choueiri TK, Patel R, et al. Impact of #ASCO Twitter Impressions on the Oncology Community. Poster presented at: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting; June 4 – 8, 2021; Virtual.
2. Owonikoko TK, Raez LE, Schwartzberg LS, et al. Perspectives on under-representation of minority patients (pts) in clinical trials. *J Clin Oncol*. 2021

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.